Hospital
Ascension Providence
Ascension Providence was paid $6.07M by Medicaid between Sep 2020 and Nov 2024, across 105 billing codes. Its largest line is 99284, emergency room visit (serious) — 37% of everything it billed.
33Billing provider infoASCENSION PROVIDENCE
WACO, TX 76712
WACO, TX 76712
33aNPI1093708679assigned 08/29/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$6.07M
24GClaims135,873
24DCodes billed105
24AFirst – last monthSep 2020 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Texas
Rank by total paid#30 of 109
Median peer was paid$1.15M
This provider vs. median5.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 2,525 | $123K | |
| 2021 | 48,113 | $1.87M | |
| 2022 | 44,956 | $2.04M | |
| 2023 | 31,281 | $1.70M | |
| 2024incomplete | 8,998 | $336K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 37% | 9,620 | 8,906 | $2.23M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 24% | 6,035 | 5,544 | $1.46M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 13,374 | 12,890 | $700K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.8% | 20,379 | 18,627 | $171K |
| 80053 | Comprehensive metabolic panel | 2.7% | 15,886 | 14,549 | $161K |
| 59025 | Fetal non-stress test | 2.5% | 1,058 | 867 | $154K |
| 71045 | Radiologic examination, chest; single view | 2.3% | 5,274 | 5,012 | $141K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.1% | 1,105 | 295 | $129K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.9% | 2,079 | 2,017 | $113K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.5% | 162 | 159 | $93K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.4% | 1,598 | 1,497 | $84K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,900 | 4,187 | $55K |
93 more codes
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 477 | $48K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,321 | $45K |
| G0378 | Hospital observation service, per hour | <1% | 1,322 | $43K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 599 | $30K |
| 86780 | <1% | 1,332 | $25K | |
| 81001 | <1% | 8,416 | $25K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,363 | $23K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 450 | $20K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 309 | $19K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 427 | $18K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,032 | $18K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 761 | $18K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 412 | $18K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,524 | $17K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,745 | $14K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 277 | $13K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 195 | $11K |
| 83690 | <1% | 2,051 | $11K | |
| 84484 | <1% | 2,213 | $11K | |
| 87486 | <1% | 162 | $10K | |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 166 | $9K |
| 87581 | <1% | 162 | $8K | |
| 86850 | <1% | 472 | $7K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,284 | $7K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 17 | $6K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 383 | $5K |
| 86803 | <1% | 273 | $5K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 98 | $5K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,016 | $5K |
| 93976 | <1% | 45 | $4K | |
| 82077 | <1% | 408 | $4K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,217 | $4K |
| G0384 | Level 5 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 414 | $4K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 163 | $4K |
| 87340 | <1% | 275 | $4K | |
| 86787 | <1% | 182 | $3K | |
| 86900 | <1% | 533 | $3K | |
| 86317 | <1% | 156 | $3K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,273 | $3K |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 231 | $3K |
| 83655 | <1% | 121 | $3K | |
| 80143 | <1% | 248 | $3K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 27 | $2K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 804 | $2K |
| 86901 | <1% | 534 | $2K | |
| 80179 | <1% | 233 | $2K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 43 | $2K |
| 80061 | Lipid panel | <1% | 636 | $2K |
| 76801 | <1% | 17 | $2K | |
| 31720 | <1% | 27 | $2K | |
| 81025 | <1% | 168 | $2K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 52 | $1K |
| 94760 | <1% | 570 | $1K | |
| 83735 | <1% | 1,027 | $1K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 563 | $1K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 685 | $1K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 93 | $1K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 464 | $1K |
| 86762 | <1% | 38 | $918.46 | |
| 97597 | <1% | 19 | $883.98 | |
| 87420 | <1% | 47 | $880.34 | |
| 83880 | <1% | 315 | $878.91 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 117 | $763.18 |
| 84702 | <1% | 74 | $747.34 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 65 | $556.86 |
| 87150 | <1% | 12 | $528.04 | |
| 82950 | <1% | 53 | $432.65 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 17 | $356.29 |
| 87070 | <1% | 39 | $340.75 | |
| 85027 | <1% | 223 | $281.82 | |
| 83605 | <1% | 256 | $274.39 | |
| 87077 | <1% | 272 | $262.80 | |
| 87186 | <1% | 236 | $260.74 | |
| 89220 | <1% | 14 | $256.28 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 54 | $247.06 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 12 | $247.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 279 | $191.48 |
| 85610 | <1% | 642 | $190.26 | |
| 85018 | <1% | 32 | $161.75 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,509 | $157.14 |
| 84439 | <1% | 15 | $155.59 | |
| J3490 | Unclassified drugs | <1% | 24 | $116.10 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 33 | $65.58 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 55 | $52.49 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 14 | $36.13 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 20 | $13.69 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 41 | $7.21 |
| 85652 | <1% | 14 | $6.70 | |
| 87205 | <1% | 12 | $3.59 | |
| A9270 | Non-covered item or service | 0% | 384 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 55 | $0.00 |
| 82962 | 0% | 917 | $0.00 | |
| J2704 | Injection, propofol, 10 mg | 0% | 26 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCORDOLA, CRAIG (CEO)
| Provider | Location | Paid |
|---|---|---|
| Ascension Seton | Lockhart, TX | $7.30M |
| Ascension Seton | Burnet, TX | $1.21M |
| Ascension Seton | Round Rock, TX | $1.00M |
| Ascension Seton | Austin, TX | $946K |
| Ascension Seton | Austin, TX | $836K |
| Ascension Seton | Luling, TX | $316K |
| Ascension Seton | Smithville, TX | $179K |
| Ascension Seton | Lockhart, TX | $109K |
| Ascension Seton | Lampasas, TX | $28K |
| Seton Family of Hospitals | Austin, TX | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.